A Phase 2/3 interventional study of florbetapir F 18 and Flortaucipir F18 in Alzheimer's Disease, sponsored by Avid Radiopharmaceuticals. Completed at 27 sites in United States. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-22.
Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 2/3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing flortaucipir in Alzheimer Disease — 4 open to participants now, 4 under way, none of them phase 3. flortaucipir · Alzheimer Disease.
Among the 22 studies testing flortaucipir in Alzheimer Disease, this one is the 2nd largest by enrollment, is one of 3 that started in 2013, is the only one in phase 2/3, and was the 2nd registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →4 of the 22 studies testing flortaucipir in Alzheimer Disease are open now, in 2 countries. Recruiting first, the newest first:
Eli Radiopharma · Sites in China
Ages 50–85 · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 50+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 60+ · Women only · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 21–80
By country, each count listing its studies:
flortaucipir: first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 20 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 7 · Phase 3 4 · Phase 4 1
First in 2013; this study’s year is marked. 3 started in 2013.
This study's enrollment of 383 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 70 across the 22 interventional studies. Of the 17 that completed or were terminated, 15 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 6 most frequent:
This study is registered under Avid Radiopharmaceuticals, one of the names counted as Eli Lilly and Company. Under that name alone:
Avid Radiopharmaceuticals is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.
99 studies in Alzheimer Disease by Eli Lilly and Company: 13 open now, 19 under way, 8 of them phase 3. Of 79 finished, 61 (77%) have results posted.
Among the 99 studies in Alzheimer Disease by Eli Lilly and Company, this one is the 17th largest by enrollment of the 95 interventional ones that give a count, is one of 7 that started in 2013, is one of 3 in phase 2/3, and was the 46th registered.
Eli Lilly and Company’s Alzheimer Disease studies by the year they started, since 2002.
2 of the studies testing flortaucipir in Alzheimer Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07580703Eli RadiopharmaA Phase I Study of [18F]Flortaucipir PET Imaging in Chinese Subjects: Safety, Pharmacokinetics, Biodistribution, Radiation Dosimetry, and Preliminary Diagnostic Efficacy | 2026-12-31 |
| NCT02740634Mayo ClinicMolecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies testing flortaucipir in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 99 in Alzheimer Disease:
This tab as a report to print or save as PDF → With an account.
A Phase 2/3 cross-sectional and longitudinal observational study evaluating imaging characteristics of flortaucipir in control subjects and patients with clinically defined MCI and AD dementia (AD).
This study was conducted in 2 phases: a Phase 2 Exploratory Phase and a Phase 3 Confirmatory Phase. An overarching goal of the Exploratory Phase of this protocol was to further investigate the pattern of flortaucipir PET imaging across the disease course, in cognitively healthy subjects through patients with cognitive decline. To accomplish this goal, the protocol investigated flortaucipir results in younger and older cognitively healthy normal volunteers and patients with clinical diagnoses for cognitive complaints, ranging from MCI to mild and moderate AD dementia. Additionally, the Exploratory Phase of this protocol investigated relationships between flortaucipir PET signal and cognitive decline over the 18-month study period.
The second, Confirmatory Phase of the study was designed to provide independent validation of the relationships observed in the exploratory analyses of the first phase. In particular, the goal of the second phase was to confirm the relationship between flortaucipir uptake in the brain as measured by PET signals at baseline and the subsequent rate of cognitive decline observed over the 18-month longitudinal follow up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exploratory Cognitively Healthy Subjects
Exploratory MCI Subjects
Exploratory AD Subjects
Confirmatory Subjects
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive an IV injection, 370 megabecquerel (MBq) (10 millicurie \[mCi\]), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline.
Drug: florbetapir F 18 · Drug: Flortaucipir F18 · Procedure: Brain PET Scan
Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline, 9 months and 18 months.
Drug: florbetapir F 18 · Drug: Flortaucipir F18 · Procedure: Brain PET Scan
Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline, 9 months and 18 months.
Drug: florbetapir F 18 · Drug: Flortaucipir F18 · Procedure: Brain PET Scan
Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 and flortaucipir at baseline.
Drug: florbetapir F 18 · Drug: Flortaucipir F18 · Procedure: Brain PET Scan
Also known as: Amyvid, 18F-AV-45
Also known as: T807, 18F-AV-1451
positron emission tomography (PET) scan of the brain
Confirmatory Phase: Relationship Between Neocortical Flortaucipir Uptake and the Subsequent Rate of Cognitive Decline
Confirm the relationship between neocortical flortaucipir uptake and the subsequent rate of cognitive decline at longitudinal follow up that was observed in the Exploratory Phase of the study. Patients were assigned to groups by majority classification of the flortaucipir positron emission tomography (PET) scan by five independent imaging physicians. Clinically meaningful cognitive and functional deterioration was defined as a 1 point or greater worsening on clinical dementia rating - sum of boxes (CDR-SB) score over the follow-up period.
Time frame: between baseline and 18 months
Exploratory Phase: Cross-sectional Flortaucipir Imaging Results
Flortaucipir standardized uptake value ratio (SUVr). A value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.
Time frame: baseline scan
Exploratory Phase: Longitudinal Change in Tau Deposition Over Time, by Amyloid Status
Assess the rate of change of tau deposition as measured by flortaucipir uptake (SUVr) over time. Change = 18 months SUVr - baseline SUVr.
Time frame: baseline and 18 months
Confirmatory Phase: Diagnostic Performance of Flortaucipir Visual Read
This analysis used dichotomized CDR-SB change as a truth standard (1 point or more worsening = true positive vs. less than 1 point worsening = true negative) to assess the diagnostic performance of baseline Advanced AD tau status (τAD++) as determined by flortaucipir scan interpretation. Sensitivity and Specificity were calculated for each of the 5 independent imaging readers. Sensitivity is the percentage of true positive cases correctly identified by an Advanced AD pattern scan. Specificity is the percentage of true negative cases correctly identified by scans that were not classified as Advanced AD pattern.
Time frame: baseline and 18 months
Exploratory Phase: Correlation Between Flortaucipir SUVr and Age
Flortaucipir standardized uptake value ratio (SUVr). A value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.
Time frame: baseline scan
Exploratory cohort subjects were enrolled starting in Dec 2013. Confirmatory cohort subjects were enrolled Dec 2014-July 2017. Exploratory cohort subjects were not eligible for the confirmatory phase.
| Milestone | Exploratory Young Cognitively Healthy Subjects | Exploratory Older Cognitively Healthy Subjects | Exploratory MCI Subjects | Exploratory AD Subjects | Confirmatory Subjects MCI | Confirmatory Subjects AD |
|---|---|---|---|---|---|---|
| Started | 16 | 58 | 98 | 51 | 0 | 0 |
| Completed | 16 | 54 | 62 | 35 | 0 | 0 |
| Not completed | 0 | 4 | 36 | 16 | 0 | 0 |
| Milestone | Exploratory Young Cognitively Healthy Subjects | Exploratory Older Cognitively Healthy Subjects | Exploratory MCI Subjects | Exploratory AD Subjects | Confirmatory Subjects MCI | Confirmatory Subjects AD |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 98 | 62 |
| Completed | 0 | 0 | 0 | 0 | 76 | 35 |
| Not completed | 0 | 0 | 0 | 0 | 22 | 27 |
Confirm the relationship between neocortical flortaucipir uptake and the subsequent rate of cognitive decline at longitudinal follow up that was observed in the Exploratory Phase of the study. Patients were assigned to groups by majority classification of the flortaucipir positron emission tomography (PET) scan by five independent imaging physicians. Clinically meaningful cognitive and functional deterioration was defined as a 1 point or greater worsening on clinical dementia rating - sum of boxes (CDR-SB) score over the follow-up period.
| Participants | Predicted to Progress | Not Predicted to Progress |
|---|---|---|
| Clinically meaningful progression | 36 | 31 |
| Did Not Progress | 27 | 37 |
Flortaucipir standardized uptake value ratio (SUVr). A value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.
| standardized uptake value ratio (SUVr) | Exploratory AD Subjects | Exploratory MCI Subjects | Exploratory Older Cognitively Healthy Subjects | Exploratory Young Cognitively Healthy Subjects |
|---|---|---|---|---|
| Aβ+ SUVr | 1.53 ± 0.037 | 1.26 ± 0.030 | 1.08 ± 0.093 | — |
| Aβ- SUVr | 1.03 ± 0.051 | 0.99 ± 0.029 | 0.98 ± 0.029 | 1.01 ± 0.039 |
Assess the rate of change of tau deposition as measured by flortaucipir uptake (SUVr) over time. Change = 18 months SUVr - baseline SUVr.
| standardized uptake value ratio (SUVr) | Exploratory AB+ (Amyloid Beta Positive) | Exploratory AB- (Amyloid Beta Negative) |
|---|---|---|
| Exploratory Phase: Longitudinal Change in Tau Deposition Over Time, by Amyloid Status | 0.052359 ± 0.008536 | 0.000655 ± 0.002394 |
This analysis used dichotomized CDR-SB change as a truth standard (1 point or more worsening = true positive vs. less than 1 point worsening = true negative) to assess the diagnostic performance of baseline Advanced AD tau status (τAD++) as determined by flortaucipir scan interpretation. Sensitivity and Specificity were calculated for each of the 5 independent imaging readers. Sensitivity is the percentage of true positive cases correctly identified by an Advanced AD pattern scan. Specificity is the percentage of true negative cases correctly identified by scans that were not classified as Advanced AD pattern.
| percentage of cases correctly identified | Independent Readers |
|---|---|
| Reader 1 Sensitivity | 59.6 (46.1 to 71.8) |
| Reader 1 Specificity | 65.5 (52.7 to 76.4) |
| Reader 2 Sensitivity | 53.8 (40.5 to 66.7) |
| Reader 2 Specificity | 65.5 (52.7 to 76.4) |
| Reader 3 Sensitivity | 55.8 (42.3 to 68.4) |
| Reader 3 Specificity | 65.5 (52.7 to 76.4) |
| Reader 4 Sensitivity | 59.6 (46.1 to 71.8) |
| Reader 4 Specificity | 65.5 (52.7 to 76.4) |
| Reader 5 Sensitivity | 50.0 (36.9 to 63.1) |
| Reader 5 Specificity | 65.5 (52.7 to 76.4) |
Flortaucipir standardized uptake value ratio (SUVr). A value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.
| standardized uptake value ratio (SUVr) | Exploratory Young Cognitively Healthy Subjects | Exploratory Older Cognitively Healthy Subjects 50-59 | Exploratory Older Cognitively Healthy Subjects 60-69 | Exploratory Older Cognitively Healthy Subjects 70-79 | Exploratory Older Cognitively Healthy Subjects >=80 |
|---|---|---|---|---|---|
| Exploratory Phase: Correlation Between Flortaucipir SUVr and Age | 1.0083 ± 0.03905 | 1.0203 ± 0.03693 | 1.0110 ± 0.04149 | 1.0010 ± 0.02604 | 1.0048 ± 0.03978 |
Collected over Adverse events (AEs) were collected at scan visits, regardless of attribution to study drug. End of study for AE reporting was 48 hours after the last study drug administration. AEs occurring after study drug administration, but outside that window were not recorded, unless considered attributable to either drug.. Non-serious events are listed at a 0.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Exploratory Younger Cognitively Healthy Subjects | 0/16 (0%) | 0/16 (0%) | 3/16 (18.8%) |
| Exploratory Older Cognitively Healthy Subjects | 0/58 (0%) | 0/58 (0%) | 17/58 (29.3%) |
| Exploratory MCI Subjects | 0/98 (0%) | 1/98 (1%) | 21/98 (21.4%) |
| Exploratory AD Subjects | 0/51 (0%) | 0/51 (0%) | 13/51 (25.5%) |
| Confirmatory Subjects MCI | 0/98 (0%) | 0/98 (0%) | 13/98 (13.3%) |
| Confirmatory Subjects AD | 0/62 (0%) | 0/62 (0%) | 0/62 (0%) |
| Event | Exploratory Younger Cognitively Healthy Subjects | Exploratory Older Cognitively Healthy Subjects | Exploratory MCI Subjects | Exploratory AD Subjects | Confirmatory Subjects MCI | Confirmatory Subjects AD |
|---|---|---|---|---|---|---|
| angina pectorisCardiac disorders | 0/16 | 0/58 | 1/98 | 0/51 | 0/98 | 0/62 |
| Event | Exploratory Younger Cognitively Healthy Subjects | Exploratory Older Cognitively Healthy Subjects | Exploratory MCI Subjects | Exploratory AD Subjects | Confirmatory Subjects MCI | Confirmatory Subjects AD |
|---|---|---|---|---|---|---|
| Injection site painGeneral disorders | 0/16 | 5/58 | 8/98 | 2/51 | 6/98 | 0/62 |
| Abdominal painGastrointestinal disorders | 1/16 | 0/58 | 0/98 | 0/51 | 0/98 | 0/62 |
| Frequent bowel movementsGastrointestinal disorders | 1/16 | 0/58 | 0/98 | 0/51 | 0/98 | 0/62 |
| ParaesthesiaNervous system disorders | 1/16 | 0/58 | 1/98 | 0/51 | 0/98 | 0/62 |
| DizzinessNervous system disorders | 1/16 | 0/58 | 0/98 | 0/51 | 2/98 | 0/62 |
| Head discomfortNervous system disorders | 1/16 | 0/58 | 0/98 | 0/51 | 0/98 | 0/62 |
| HeadacheNervous system disorders | 0/16 | 3/58 | 3/98 | 1/51 | 4/98 | 0/62 |
| HypertensionVascular disorders | 0/16 | 1/58 | 0/98 | 2/51 | 0/98 | 0/62 |
| FatigueGeneral disorders | 0/16 | 2/58 | 1/98 | 0/51 | 0/98 | 0/62 |
| Blood pressure increasedInvestigations | 0/16 | 2/58 | 2/98 | 1/51 | 0/98 | 0/62 |
| Age, Continuous(years) | Exploratory Young Cognitively Healthy Subjects | Exploratory Older Cognitively Healthy Subjects | Exploratory MCI Subjects | Exploratory AD Subjects | Confirmatory Subjects MCI | Confirmatory Subjects AD | Total |
|---|---|---|---|---|---|---|---|
| Mean | 28.9 ± 4.88 | 68.5 ± 10.29 | 70.8 ± 9.3 | 73.9 ± 9.01 | — | — | 67.9 ± 14.36 |
| Age, Continuous(years) | Exploratory Young Cognitively Healthy Subjects | Exploratory Older Cognitively Healthy Subjects | Exploratory MCI Subjects | Exploratory AD Subjects | Confirmatory Subjects MCI | Confirmatory Subjects AD | Total |
|---|---|---|---|---|---|---|---|
| Mean | — | — | — | — | 72.5 ± 9.69 | 73.6 ± 9.53 | 72.9 ± 9.61 |
| Sex: Female, Male(Participants) | Exploratory Young Cognitively Healthy Subjects | Exploratory Older Cognitively Healthy Subjects | Exploratory MCI Subjects | Exploratory AD Subjects | Confirmatory Subjects MCI | Confirmatory Subjects AD | Total |
|---|---|---|---|---|---|---|---|
| Female | 7 | 26 | 49 | 28 | 44 | 30 | 184 |
| Male | 9 | 32 | 49 | 23 | 54 | 32 | 199 |
| Ethnicity (NIH/OMB)(Participants) | Exploratory Young Cognitively Healthy Subjects | Exploratory Older Cognitively Healthy Subjects | Exploratory MCI Subjects | Exploratory AD Subjects | Confirmatory Subjects MCI | Confirmatory Subjects AD | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 4 | 0 | 5 | 4 | 15 |
| Not Hispanic or Latino | 15 | 57 | 94 | 51 | 93 | 58 | 368 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Exploratory Young Cognitively Healthy Subjects | Exploratory Older Cognitively Healthy Subjects | Exploratory MCI Subjects | Exploratory AD Subjects | Confirmatory Subjects MCI | Confirmatory Subjects AD | Total |
|---|---|---|---|---|---|---|---|
| Asian | 1 | 1 | 1 | 0 | 1 | 1 | 5 |
| Black or African American | 3 | 9 | 7 | 2 | 3 | 0 | 24 |
| White | 11 | 47 | 89 | 47 | 94 | 61 | 349 |
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other | 1 | 1 | 1 | 1 | 0 | 0 | 4 |
| Clinical Dementia Rating - Sum of Boxes (CDR-SB)(units on a scale) | Exploratory Young Cognitively Healthy Subjects | Exploratory Older Cognitively Healthy Subjects | Exploratory MCI Subjects | Exploratory AD Subjects | Confirmatory Subjects MCI | Confirmatory Subjects AD | Total |
|---|---|---|---|---|---|---|---|
| Mean | — | — | — | — | 2.8 ± 1.73 | 4.3 ± 1.69 | 3.4 ± 1.88 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2013 to primary completion in Jul 2017, 43 months.
Results were first posted in Aug 2020, 3 years after primary completion. A results delay was requested in Jul 2018.
Of 28 phase 2/3 interventional studies under Alzheimer Disease, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 59. This study's 43 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Flortaucipir